Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 13, Issue 3, 2004, Pages 138-140

  Willmot, Mark ^a   Zhao, Lian ^a   Heptinstall, Stan ^a   Bath, Philip ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antiplatelet therapy; ischemic stroke; secondary stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ANAMNESIS; ANTICOAGULATION; ARTICLE; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; DYSPEPSIA; HUMAN; LABORATORY TEST; MALE; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 3042715252     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2004.03.001     Document Type: Article

References (11)

1. Diener H., Cunha L., Forbes C. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 143:1996;1-13
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339
3. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 338:1991;1345-1349
4. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial Final results. J Neurol Neurosurg Psychiatry. 54:1991;1044-1054
5. Hass W.K., Easton J.D., Adams H.P.J., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 321:1989;501-507
6. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after TIA or minor stroke. Lancet. 342:1993;1255-1262
7. International Stroke Trial Collaborative Group. The international stroke trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet. 349:1997;1569-1581
8. Yusuf S., Fox K.A.A., Tognoni G., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502
9. ESPS Group. European stroke prevention study. Stroke. 21:1990;1122-1130
10. Diener H.C., Bogousslavsky J., Brass L.M., et al. Management of atherothrombosis with clopidogrel in high risk patients with recent transient ischemic attack or ischemic stroke (MATCH) Study design and baseline data. Cerebrovasc Dis. 17:2004;253-261
11. Zhao L., Bath P., Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol. 134:2001;353-358